TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.

Hideaki Bando,Daisuke Kotani,Takahiro Tsushima,Hiroki Hara,Shigenori Kadowaki,Ken Kato,Keisho Chin,Kensei Yamaguchi,Shun-ichiro Kageyama,Hidehiro Hojo,Masashi Wakabayashi,Miki Fukutani,Yosuke Togashi,Nozomu Fuse,Hiroyoshi Nishikawa,Takashi Kojima

TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.

2019

Hideaki Bando
Daisuke Kotani
Takahiro Tsushima
Hiroki Hara
Shigenori Kadowaki
Ken Kato
Keisho Chin
Kensei Yamaguchi
Shun-ichiro Kageyama
Hidehiro Hojo
Masashi Wakabayashi
Miki Fukutani
Yosuke Togashi
Nozomu Fuse
Hiroyoshi Nishikawa
Takashi Kojima

TPS4141Background: The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using 5-FU plus cisplatin. ...

Keywords:

Chemoradiotherapy
Phases of clinical research
Carcinoma
Cell
Cisplatin
Oncology
Pathology
Internal medicine
Medicine
Atezolizumab
esophageal squamous cell carcinoma
in patient
locally advanced
definitive chemoradiotherapy
Standard treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations